CBFB Break-Apart FISH Testing: An Analysis of 1629 AML Cases with a Focus on Atypical Findings and Their Implications in Clinical Diagnosis and Management
- PMID: 34771519
- PMCID: PMC8582369
- DOI: 10.3390/cancers13215354
CBFB Break-Apart FISH Testing: An Analysis of 1629 AML Cases with a Focus on Atypical Findings and Their Implications in Clinical Diagnosis and Management
Abstract
Fluorescence in situ hybridization (FISH) is a confirmatory test to establish a diagnosis of inv(16)/t(16;16) AML. However, incidental findings and their clinical diagnostic implication have not been systemically studied. We studied 1629 CBFB FISH cases performed in our institution, 262 (16.1%), 1234 (75.7%), and 133 (8.2%) were reported as positive, normal, and abnormal, respectively. The last included CBFB copy number changes (n = 120) and atypical findings such as 3'CBFB deletion (n = 11), 5'CBFB deletion (n = 1), and 5'CBFB gain (n = 1). Correlating with CBFB-MYH11 RT-PCR results, totally 271 CBFB rearrangement cases were identified, including five with discrepancies between FISH and RT-PCR due to new partner genes (n = 3), insertion (n = 1), or rare CBFB-MYH11 variant (n = 1) and eight with 3'CBFB deletion. All cases with atypical findings and/or discrepancies presented clinical diagnostic challenges. Correlating FISH signal patterns and karyotypes, additional chromosome 16 aberrations (AC16As) show impacts on the re-definition of a complex karyotype and prognostic prediction. The CBFB rearrangement but not all AC16As will be detected by NGS-based methods. Therefore, FISH testing is currently still needed to provide a quick and straightforward confirmatory inv(16)/t(16;16) AML diagnosis and additional information related to clinical management.
Keywords: CBFB rearrangement; CBFB-MYH11; FISH; RT-PCR; additional chromosome16 aberrations (AC16As); atypical findings; next-generation sequencing (NGS).
Conflict of interest statement
The authors declare no conflict of interest.
Figures





Similar articles
-
PPP1R7 Is a Novel Translocation Partner of CBFB via t(2;16)(q37;q22) in Acute Myeloid Leukemia.Genes (Basel). 2022 Jul 29;13(8):1367. doi: 10.3390/genes13081367. Genes (Basel). 2022. PMID: 36011278 Free PMC article.
-
3'CBFB deletion in CBFB-rearranged acute myeloid leukemia retains morphological features associated with inv(16), but patients have higher risk of relapse and may require stem cell transplant.Ann Hematol. 2022 Apr;101(4):847-854. doi: 10.1007/s00277-022-04767-1. Epub 2022 Feb 20. Ann Hematol. 2022. PMID: 35184217
-
Inversion and deletion of 16q22 defined by array CGH, FISH, and RT-PCR in a patient with AML.Cancer Genet. 2011 Jun;204(6):344-7. doi: 10.1016/j.cancergen.2011.05.005. Cancer Genet. 2011. PMID: 21763633
-
Acute myeloid leukaemia (FAB AML-M4Eo) with cryptic insertion of cbfb resulting in cbfb-Myh11 fusion.Hematol Oncol. 2017 Sep;35(3):385-389. doi: 10.1002/hon.2268. Epub 2015 Nov 2. Hematol Oncol. 2017. PMID: 28906004 Review.
-
Acute myeloid leukemia with inv(16) with CBFB-MYH11, 3'CBFB deletion, variant t(9;22) with BCR-ABL1, and del(7)(q22q32) in a pediatric patient: case report and literature review.Cancer Genet Cytogenet. 2010 Jul 1;200(1):54-9. doi: 10.1016/j.cancergencyto.2010.03.001. Cancer Genet Cytogenet. 2010. PMID: 20513535 Review.
Cited by
-
PPP1R7 Is a Novel Translocation Partner of CBFB via t(2;16)(q37;q22) in Acute Myeloid Leukemia.Genes (Basel). 2022 Jul 29;13(8):1367. doi: 10.3390/genes13081367. Genes (Basel). 2022. PMID: 36011278 Free PMC article.
References
-
- Arber D.A., Brunning R.D., Le Beau M.M., Falini B.J.W.V. Acute myeloid leukemia with recurrent genetic abnormalities. In: Swerdlow S.H., Campo E., Harris N.L., Jaffe E.S., Pileri S.A., Stein H., Thiele J., Arber D.A., Hasserjian R.P., Le Beau M.M., et al., editors. WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues. 4th ed. International Agency for Research on Cancer; Lyon, France: 2016. pp. 130–149.
-
- Grimwade D., Walker H., Oliver F., Wheatley K., Harrison C., Harrison G., Rees J., Hann I., Stevens R., Burnett A., et al. The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children’s Leukaemia Working Parties. Blood. 1998;92:2322–2333. doi: 10.1182/blood.V92.7.2322. - DOI - PubMed
-
- Grimwade D., Hills R.K., Moorman A.V., Walker H., Chatters S., Goldstone A.H., Wheatley K., Harrison C.J., Burnett A.K. Refinement of cytogenetic classification in acute myeloid leukemia: Determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010;116:354–365. doi: 10.1182/blood-2009-11-254441. - DOI - PubMed
-
- Hernández J.M., González M.B., Granada I., Gutiérrez N., Chillón C., Ramos F., Ribera J.M., González M., Feliu E., San Miguel J. Detection of inv(16) and t(16;16) by fluorescence in situ hybridization in acute myeloid leukemia M4Eo. Haematologica. 2000;85:481–485. - PubMed
LinkOut - more resources
Full Text Sources